# Forus

> AI network that moves specialty prescriptions from doctor order through insurance, assistance, and pharmacy — free for clinics and patients, paid by biopharma.

## Why it is interesting

September 8, 2026 $150M Series C at $3B — tripling a ~$1B May mark — underwrites an access layer where the company says more than a third of specialty prescriptions never reach a first dose.

## Profile

- **Latest funding:** Series C — $150M (September 2026)
- **Latest known valuation:** $3B (September 2026)
- **Total disclosed equity funding:** $150M
- **Stage:** growth
- **Status:** private
- **Industries:** healthtech, ai-ml, enterprise-saas
- **Coverage:** full
- **Last updated:** 2026-09-09
- **Latest funding investors:** Bain Capital Ventures, Thrive Capital, General Catalyst, Accel, Redpoint Ventures, BoxGroup, Neo

## Key facts

- Series C (Sep 8, 2026): $150M at $3B led by Bain Capital Ventures (company)
- Total disclosed funding >$300M; May 2026 rebrand from Tandem cited >$160M cumulative at ~$1B
- Company claims millions of patients, 85% of U.S. residential ZIP codes, all 50 states
- 9 of top 15 global biopharma companies work with Forus (company)
- Product free for doctors and patients; monetization via biopharma network

## Funding history

- Series C · $150M · September 2026
  Source: https://forus.com/stories/forus-series-c

## Investors in our directory

- https://venturecapitaltracker.com/fund/bain-capital-ventures
- https://venturecapitaltracker.com/fund/thrive-capital
- https://venturecapitaltracker.com/fund/general-catalyst
- https://venturecapitaltracker.com/fund/redpoint-ventures
- https://venturecapitaltracker.com/fund/box-group
- https://venturecapitaltracker.com/fund/neo

## Related articles

- https://venturecapitaltracker.com/2026-forus-150m-series-c-3b-bain
- https://venturecapitaltracker.com/2026-september-8-9-investment-news-cognition-space-health

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** September 9, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/forus